ADJUVANT CETUXIMAB AND CHEMORADIOTHERAPY USING EITHER CISPLATIN OR DOCETAXEL IN TREATING PATIENTS WITH RESECTED STAGE III OR STAGE IV SQUAMOUS CELL CARCINOMA OR LYMPHOEPITHELIOMA OF THE HEAD AND NECK: